Cyclopharm Director Increases Indirect Shareholding via Share Purchase Plan

Cyclopharm Limited ( (AU:CYC) ) has shared an announcement.

Cyclopharm Limited has disclosed a change in director Kevin Michael John Barrow’s indirect interest in the company’s ordinary shares, in line with ASX listing rule requirements. Barrow’s relevant interest, held through the Melissa Elizabeth Barrow Trust via BT Panorama Investments, increased by 5,263 shares to a total of 30,347 ordinary shares following his participation in the company’s Share Purchase Plan.

The shares were acquired on 12 March 2026 for a cash consideration of $4,999.85, and no shares were disposed of as part of the transaction. The company also confirmed there was no related change in any director’s interests in contracts and that the trades did not occur during a closed period requiring prior written clearance, reinforcing Cyclopharm’s adherence to regulatory and governance standards.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited is an Australian-listed healthcare company operating in the medical sector, with its securities traded on the ASX. The company’s capital structure includes ordinary shares, and its governance disclosures follow ASX listing rules and Australian Corporations Act requirements regarding directors’ interests in securities.

Average Trading Volume: 89,869

Technical Sentiment Signal: Sell

Current Market Cap: A$88.05M

For an in-depth examination of CYC stock, go to TipRanks’ Overview page.